DXS International (AQSE:DXSP) Ending Cash Position: £0.43 Mil (As of Apr. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is DXS International Ending Cash Position?

DXS International AQSE:DXSP Ending Cash Position is £0.43 Mil as of Apr. 2025. The stock has 5 warning signs investors should review.

DXS International's Ending Cash Position for the quarter that ended in Apr. 2025 was £0.43 Mil.

DXS International's quarterly Ending Cash Position declined from Apr. 2023 (£0.37 Mil) to Apr. 2024 (£0.09 Mil) but then increased from Apr. 2024 (£0.09 Mil) to Apr. 2025 (£0.43 Mil).

DXS International's annual Ending Cash Position declined from Apr. 2023 (£0.37 Mil) to Apr. 2024 (£0.09 Mil) but then increased from Apr. 2024 (£0.09 Mil) to Apr. 2025 (£0.43 Mil).

DXS International Ending Cash Position Related Terms

DXS International Ending Cash Position Historical Data

* Premium members only.

The historical data trend for DXS International's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DXS International Ending Cash Position Chart

DXS International Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.45 0.37 0.09 0.43

DXS International Semi-Annual Data
Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.79 0.45 0.37 0.09 0.43

DXS International Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

DXS International's Ending Cash Position for the fiscal year that ended in Apr. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.09+0.339
=0.43

DXS International's Ending Cash Position for the quarter that ended in Apr. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.09+0.339
=0.43

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of £0.43 Mil mean?
DXS International (AQSE:DXSP) has a Ending Cash Position of £0.43 Mil as of Apr. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on DXS International and its competitors.
Is DXS International's Ending Cash Position too high?
DXS International's current Ending Cash Position is £0.43 Mil.
How does DXS International's Ending Cash Position compare to VEEV and BTSG?
DXS International's Ending Cash Position of £0.43 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Healthcare Providers & Services company?
A good Ending Cash Position depends on the Healthcare Providers & Services industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on DXS International and its competitors. DXS International's current Ending Cash Position is £0.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
Based on GuruFocus' analysis, DXS International (AQSE:DXSP) is currently considered Fairly Valued. The stock's GF Value™ is £0.02, compared to a current price of £0.02 — trading 5% above its estimated fair value. The current Ending Cash Position is £0.43 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For DXS International (AQSE:DXSP), the current Ending Cash Position is £0.43 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DXS International Business Description

Address 119 Saint Mary’s Road, Market Harborough, London, Leicestershire, GBR, LE16 7DT
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.